Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320060 | 0.90 | PTPN1 (0.53) | PTPN1ALDH1A1BRD4PDE3BPDE3A | |
| SCHEMBL21601607 | 0.90 | PTPN1 (0.53) | PTPN1ALDH1A1BRD4PDE3BPDE3A | |
| SCHEMBL14402249 | 0.90 | BRD4 (0.51) | PTPN1ALDH1A1BRD4PDE3BPDE3A | |
| SCHEMBL6510637 | 0.86 | ALDH1A1 (0.58) | PTPN1ALDH1A1PDE3BPDE3AP2RY12 | |
| SCHEMBL6602851 | 0.85 | BRD4 (0.53) | PTPN1BRD4PDE3BPDE3AP2RY12 | |
| SCHEMBL1124419 | 0.84 | ALDH1A1 (0.58) | PTPN1ALDH1A1PDE3BPDE3AP2RY12 | |
| SCHEMBL5879172 | 0.84 | ALDH1A1 (0.58) | ALDH1A1PDE3BPDE3AP2RY12MAOB | |
| SCHEMBL21601619 | 0.84 | ALDH1A1 (0.54) | PTPN1ALDH1A1CYP1A2CYP2C19LMNA | |
| SCHEMBL5545270 | 0.84 | KDM4E (0.54) | PTPN1ALDH1A1BRD4PDE3BPDE3A | |
| SCHEMBL12238287 | 0.84 | BRD4 (0.52) | PTPN1BRD4PDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585517-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004062663-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
| EP-1170009-B1 | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-0880519-B1 | THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-1170009-A2 | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-5994378-A | ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0880519-A1 | THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997027190-A1 | THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | PTPN1 1256/4885ALDH1A1 1506/4885BRD4 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.